This article is more than 5 years old. Information may no longer be current.
Good results reported for AcrySof phakic IOL
Click Here to Manage Email Alerts
STOCKHOLM, Sweden — A multicenter European clinical investigation of the Alcon AcrySof angle-supported phakic IOL shows that this lens model has excellent visual results and, so far, none of the drawbacks of other angle-supported IOLs, according to two surgeons.
In particular, endothelial cell density seems to remain relatively stable, with a minimal loss of 1.7% per year from 6 months to 2 years.
"Thanks to this new lens, there might be a future for angle-supported lenses," said Joseph Colin, MD, at the European Society of Cataract and Refractive Surgeons meeting.
The unique design of this IOL seems to be capable of maintaining a safe distance from the endothelium and to have a firm but gentle hold to the angle, he said.
Unilateral implantation was performed in 190 patients, 99 with 2 years of follow-up. Follow-up is planned for 5 years.
"At 2 years, best corrected visual acuity of 20/25 or better has been achieved by 98.4% of the patients. Refraction is within ±0.5 D of target in 78% of the patients. More than half of the patients gained one to two visual acuity lines," Michael Knorz, MD, said.
The most common complication was increased IOP due to incomplete viscoelastic removal, Dr. Knorz said. No persistent cases of corneal edema, cystoid macular edema or iritis were reported.